Top KOLs Discussing INTerpath-001
INTerpath-001 Key Slides & Visuals
INTerpath-001 Top Tweets
𝕏🧬 HOW DOES A PERSONALIZED mRNA CANCER VACCINE ACTUALLY WORK? As an oncologist, and also as a university professor, I strongly believe that understanding how a new treatment works is often the best way to understand why it may eventually change our clinical practice. So, what exactly is a personalized mRNA cancer vaccine? The concept is both sophisticated and surprisingly intuitive. 1️⃣ Start with the patient's own tumor 🧬 Every cancer is genetically different. By sequencing tumor DNA and RNA, and comparing this information with normal tissue , we can identify tumor-specific mutations. Some of these mutations generate abnormal proteins that are not present in healthy cells. These are called neoantigens. And importantly, they can become molecular "flags" allowing the immune system to distinguish cancer cells from normal cells. 2️⃣ Select the best targets 🎯 Not every mutation will generate an effective immune response. Bioinformatic algorithms therefore analyze the patient's tumor and predict which neoantigens are most likely to be recognized by their immune system. In the case of intismeran autogene, up to 34 patient-specific neoantigens can be selected. 3️⃣ Build an individualized mRNA therapy 💉 Here comes the fascinating part. A synthetic mRNA sequence encoding those selected neoantigens is manufactured specifically for that individual patient. Think about what this means. We are no longer simply choosing the best available drug for a patient. We are manufacturing a treatment based on the molecular identity of that patient's own cancer. 4️⃣ Teach the immune system what to recognize 🛡️ After administration, the mRNA enters cells and provides the instructions to produce the selected neoantigens. These neoantigens are processed and presented to the immune system, activating tumor-specific CD4+ and CD8+ T cells. The objective is to generate an immune response capable of recognizing cells carrying those same neoantigens. 5️⃣ Let T cells search for the cancer 🔎 Those activated T cells can then recognize tumor cells displaying the corresponding antigens and potentially destroy them. This is why combining personalized vaccination with PD-1 blockade such as pembrolizumab makes so much biological sense: 🎯 The vaccine may teach the immune system WHAT to attack. 🔓 Checkpoint inhibition may help the immune system KEEP attacking it. And this is where, in my view, the concept becomes much bigger than one drug or one tumor type. For many years, we have defined precision oncology as: “the right treatment for the right patient.” Personalized mRNA vaccines introduce an even more ambitious paradigm: “a treatment designed and manufactured specifically from the molecular characteristics of one patient's cancer.” @OncoAlert @_SEOM @moderna_tx @GEPAC_ Figure adapted from: doi:10.3390/cancers17091408.
𝕏mRNA-4157-P201/KEYNOTE-942: Pembrolizumab +/- mRNA-4157 (V940, personalized cancer vaccine) as adjuvant therapy in resectable melanoma, a randomized phase 2, open-label study by Dr. Jeffrey Weber. What happens in melanoma will happen in lung cancer. #AACR23 #LCSM https://t.co/Rebrpl0Ltb
𝕏Don’t miss the data at #ESMO2026 https://t.co/vFiJ0ruccU [QUOTED] JUST IN and via @Merck + @moderna_tx: A landmark moment for cancer immunotherapy. 🎯 Phase 3 INTerpath-001 is positive: the individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) + pembrolizumab significantly improved both RFS/DMFS vs pembrolizumab alone after resection of high-risk melanoma. For years, the idea of designing a treatment around the unique mutations of each patient’s tumor seemed aspirational. Now we have the first positive Phase 3 trial (N=1137) of an individualized neoantigen therapy—and of an mRNA-based cancer therapy. Personalized cancer vaccines are moving from promise to reality. Now we need to see the magnitude of benefit, durability, and ultimately OS. But today is an important day for the field—and hopefully for our patients. 👏 Congrats to #CathyWu @DanaFarber for her trailblazing research that is materializing in tangible outcomes! At @DanaFarber_GU we are closely working with Cathy + @DFCI_NeoVax team on several GU protocols, after our @Nature work with @BraunMDPhD et al (https://t.co/BdbKJqMKOw) https://t.co/Akd0XQt3ml
𝕏The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer https://t.co/cv4iXW11mw
𝕏Positive phase 3 data for adjuvant pembro +/- personalized mRNA-based neoantigen vaccine for melanoma just announced by Merck and Moderna. Welcome to the future! https://t.co/rlKAvv7sbo https://t.co/BxYKh4NKKw
𝕏Newly minted twins- Intismeran and pembro are feeling pretty good today https://t.co/62jEnUt1mk https://t.co/5F8aw2rFqf [QUOTED] Are you into Intismeran- the new “individualized neoantigen therapy” (graciously avoiding the term “vaccine”) from Merck/Moderna? If you haven’t- you should! Maybe biggest news in onc for some time along w daraxonrasib- positive results in pivotal melanoma trial as to RFS improvement of this Space age technology which still makes my head spin- whole genome seq- neoantigen selection- personalized “INT” delivered to your patient in just a few weeks… and it works! Many studies ongoing in lung/bladder etc- eager to learn results (and continue to offer to our pts at Monte @BrendonStilesMD !) Now Back to the Future and let’s keep enrolling!
𝕏JUST IN and via @Merck + @moderna_tx: A landmark moment for cancer immunotherapy. 🎯 Phase 3 INTerpath-001 is positive: the individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) + pembrolizumab significantly improved both RFS/DMFS vs pembrolizumab alone after resection of high-risk melanoma. For years, the idea of designing a treatment around the unique mutations of each patient’s tumor seemed aspirational. Now we have the first positive Phase 3 trial (N=1137) of an individualized neoantigen therapy—and of an mRNA-based cancer therapy. Personalized cancer vaccines are moving from promise to reality. Now we need to see the magnitude of benefit, durability, and ultimately OS. But today is an important day for the field—and hopefully for our patients. 👏 Congrats to #CathyWu @DanaFarber for her trailblazing research that is materializing in tangible outcomes! At @DanaFarber_GU we are closely working with Cathy + @DFCI_NeoVax team on several GU protocols, after our @Nature work with @BraunMDPhD et al (https://t.co/BdbKJqMKOw) https://t.co/Akd0XQt3ml
𝕏🔥INTerpath-002: Adj Pembrolizumab + V940 (mRNA-4157) vs. Pembro 🆙 @Merck @moderna_tx 🎯Primary completion: 2030-06-25 👥Patients: Completely resected (R0) Stage II, IIIA or IIIB (N2) NSCLC, post-surgery and adjuvant chemotherapy 3⃣Phase III ⚖️Intismeran autogene (mRNA-4157) + pembrolizumab ⚖️Pembrolizumab alone (+ placebo) 🔢NCT06077760 #LCSM @OncoAlert @Larvol
𝕏💉 Personalized mRNA cancer vaccines like intismeran autogene (V940/mRNA-4157) can work in genitourinary cancers? Three ongoing studies are particularly interesting. 🔵 KIDNEY CANCER — INTerpath-004 This randomized, double-blind Phase II study is evaluating adjuvant: V940 + pembrolizumab vs placebo + pembrolizumab following nephrectomy in patients with RCC at increased risk of recurrence. The primary endpoint is disease-free survival, with distant metastasis-free survival and overall survival among the secondary endpoints. If individualized neoantigen vaccination works in RCC, it could therefore tell us something very important about the biology of this platform: its potential may extend beyond simply selecting tumors with very high mutational burden. 🟠 MUSCLE-INVASIVE BLADDER CANCER — INTerpath-005 Here the development strategy is even more ambitious. INTerpath-005 is a Phase I/II program exploring V940 in two different settings. One cohort evaluates a perioperative strategy combining: V940 + pembrolizumab + enfortumab vedotin in cisplatin-ineligible patients undergoing radical cystectomy. Another randomized cohort evaluates adjuvant: V940 + pembrolizumab vs placebo + pembrolizumab in patients with high-risk resected muscle-invasive urothelial carcinoma. Could we combine three completely different therapeutic principles? 💥 EV → rapidly kills Nectin-4-expressing tumor cells 🔓 Pembrolizumab → releases PD-1-mediated immune inhibition 🎯 V940 → potentially generates an individualized T-cell response against that patient's unique tumor neoantigens ADC + checkpoint inhibition + personalized vaccination. Three mechanisms. One objective: eradicate micrometastatic residual disease before it can become clinically visible. And there is another bladder cancer study that should not be overlooked. 🟡 NON-MUSCLE-INVASIVE BLADDER CANCER — INTerpath-011 This ongoing randomized Phase II study is evaluating: V940 + BCG vs BCG alone in treatment-naïve high-risk NMIBC. I find this particularly intriguing. BCG has successfully exploited the immune system against bladder cancer for decades. Combining this established local immunotherapy with a systemic, individualized neoantigen-directed immune strategy represents a completely different way of thinking about treatment intensification in early bladder cancer. Of course, none of these studies is guaranteed to reproduce what we have seen in melanoma. For someone who has spent much of his career developing new treatments for kidney and bladder cancer, I find the possibility particularly exciting. Precision oncology has traditionally meant finding the right drug for the right patient. Personalized mRNA vaccines introduce an even more ambitious concept: creating a different drug for each individual patient's cancer. @OncoAlert @_SEOM @GuardConsortium @urotoday @GUOncologyNow @LACOG_group @GEPAC_
𝕏A milestone for individualised neoantigen therapy and encouraging for the broader V940 (mRNA-4157) programme! Will the melanoma signal translate to GU cancers? - INTerpath-004: V940 + pembro vs pembro in adjuvant RCC - INTerpath-005: V940 + pembro vs pembro in MIUC @OncoAlert https://t.co/Q16XNfFHJX https://t.co/leaRqALAaQ
About the INTerpath-001 Trial
Intismeran autogene is an mRNA-based individualized neoantigen therapy: each patient’s resected tumor is sequenced, up to 34 tumor-specific neoantigens are selected, and a single mRNA encoding them is manufactured for that patient, then given with pembrolizumab. INTerpath-001 tested this combination against pembrolizumab alone as adjuvant therapy in completely resected stage IIB–IV cutaneous melanoma.
On August 19, 2026 the trial met both its primary endpoint (recurrence-free survival) and key secondary endpoint (distant metastasis-free survival) with statistically significant, clinically meaningful improvements — the first positive Phase 3 for an individualized neoantigen therapy. Sibling INTerpath trials are ongoing in NSCLC, bladder cancer and first-line advanced melanoma. Principal investigator Professor Georgina Long (Melanoma Institute Australia) said the combination “has the potential to establish a new treatment paradigm in the adjuvant melanoma setting.” Magnitude of benefit has not been disclosed; full results will be presented at the ESMO Congress 2026 Presidential Symposium (LBA1, October 24, 2026, Madrid) and OS follow-up continues.
Trial Methodology & Results
Study Design
Randomized (2:1), double-blind, placebo- and active-comparator-controlled global Phase 3. 1,137 patients enrolled following complete surgical resection.
Population
Completely resected, high-risk stage IIB–IV cutaneous melanoma; no prior systemic therapy.
Interventions
Intismeran autogene 1 mg IM q3w (up to 9 doses) + pembrolizumab 400 mg q6w (up to 9 cycles, ~1 year) vs placebo + pembrolizumab.
Endpoints
Primary: recurrence-free survival (RFS). Key secondary: distant metastasis-free survival (DMFS). Other secondary: OS, safety, quality of life (EORTC QLQ-C30).
Manufacturing
Each dose is patient-individualized: tumor + blood sequencing → neoantigen selection → single-mRNA manufacture → IM administration (see Dr. Tarhini’s workflow slide above).
Sponsors
Merck Sharp & Dohme (sponsor) with ModernaTX (collaborator); intismeran jointly developed by Merck and Moderna.
Topline efficacy (announced Aug 19, 2026 — numbers pending presentation)
Statistically significant and clinically meaningful improvements in BOTH recurrence-free survival (primary) and distant metastasis-free survival (key secondary) versus pembrolizumab alone. Effect sizes, confidence intervals and event counts have not been disclosed and will be presented at the ESMO Congress 2026 Presidential Symposium (LBA1, October 24, 2026, Madrid); the trial continues per protocol to evaluate overall survival.
First positive Phase 3 for an individualized neoantigen therapySource: Merck/Moderna topline press release
Clinical Implications
⚠ Investigational. If the presented magnitude holds up, adjuvant melanoma would gain its first individualized therapy on top of PD-1 blockade — and the INT modality gains randomized Phase 3 validation with read-through to the sibling INTerpath programs (NSCLC, bladder, 1L melanoma). Physicians on this page flag the open questions: magnitude of benefit, durability, OS, manufacturing turnaround and cost.
Source: Merck/Moderna topline PRINTerpath-001 in the News
INTerpath-001 FAQ
What is the INTerpath-001 trial?
INTerpath-001 (NCT05933577, V940-001) is a randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 trial of adjuvant intismeran autogene (V940 / mRNA-4157), an mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with pembrolizumab (Keytruda) versus pembrolizumab alone in patients with completely resected, high-risk stage IIB-IV cutaneous melanoma. It enrolled 1,137 patients, randomized 2:1 to intismeran (1 mg every three weeks for up to nine doses) plus pembrolizumab (400 mg every six weeks for up to nine cycles, approximately one year) versus pembrolizumab alone.
What did INTerpath-001 show?
Per the August 19, 2026 topline announcement, the trial met both its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS), with statistically significant and clinically meaningful improvements versus pembrolizumab alone. Numeric results have not been disclosed; full results will be presented at the ESMO Congress 2026 Presidential Symposium (LBA1, October 24, 2026, Madrid), presented by Professor Georgina V. Long. The trial continues to evaluate other secondary endpoints including overall survival. Safety was consistent with previously reported studies of the combination, with no new safety signals.
What is intismeran autogene?
An mRNA-based individualized neoantigen therapy (INT): each patient's resected tumor is sequenced, up to 34 patient-specific neoantigens are encoded on a single mRNA, and the therapy is manufactured individually to train that patient's immune system to recognize and attack their cancer. It was formerly known as mRNA-4157 or V940.
How do these results relate to KEYNOTE-942?
KEYNOTE-942 was the randomized Phase 2b antecedent (n=157, resected stage III/IV melanoma). It showed a consistent RFS benefit at every analysis - primary (Nov 2022 cut): HR 0.561 (95% CI 0.309-1.017); 3-year: HR 0.510 (0.288-0.906); 5-year: HR 0.510 (0.294-0.887), with 5-year DMFS HR 0.411 (0.200-0.843) - per the ASCO 2026 presentation and the topline PR. Important: hazard-ratio figures circulating on announcement day are these KEYNOTE-942 Phase 2b numbers - INTerpath-001's own magnitude of benefit has not yet been disclosed.
Is intismeran autogene approved?
No. Intismeran autogene plus pembrolizumab is investigational and not approved by the FDA or any other regulator. Merck and Moderna stated they will engage with regulators on filing submissions based on INTerpath-001. This is the first positive Phase 3 trial for an individualized neoantigen therapy.